Novel immunosuppressants

Pediatric Transplantation

Volumn 8, Issue 6, 2004, Pages 594-599

  Krieger, Nancy R ^a   Emre, Sukru ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Costimulation; Immunosuppression; Pediatric transplantation; T cell depletion

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CALCINEURIN INHIBITOR; CD40 LIGAND; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID;

ACNE; ALOPECIA; ALPHA CHAIN; ANESTHESIA INDUCTION; BONE MARROW SUPPRESSION; CATARACT; CONFERENCE PAPER; DEPLETION; DIABETES MELLITUS; DIABETOGENESIS; FACE DYSMORPHIA; GASTROINTESTINAL DISEASE; GINGIVA HYPERPLASIA; GRAFT REJECTION; GRAFT SURVIVAL; GROWTH RETARDATION; GYNECOMASTIA; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; LONG TERM CARE; MAINTENANCE THERAPY; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PROTEIN EXPRESSION; SHORT COURSE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CD40 LIGAND; CHILD; GUANIDINES; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LYMPHOCYTE DEPLETION; PROPYLENE GLYCOLS; SPHINGOSINE; T-LYMPHOCYTES;

EID: 11144231798     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2004.00237.x     Document Type: Conference Paper

References (64)

1. KAHAN BD, RAJAGOPALAN PR, HALL M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999: 67: 276-284.
2. BUMGARDENER GL, HARDIE I, JOHNSON RW, et al. Phase III Daclizumab Study Group. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001: 72: 839-845.
3. VESTER U, KRANZ B, TESTA G et al. Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients. Pediatr Transplantation 2001: 5: 297-301.
4. GARCIA CD, BARROS VR, SCHNEIDER L, ALVES MD, SILVEIRA CG, GARCIA VD. IL-2 antibody induction and the outcome of pediatric renal transplants. Transplant Proceedings 2002: 34: 2914-2915.
5. STRASSBURG A, PFISTER E-D, ARNING A, NASHAN B, EHRICH JHH, MELTER M. Basiliximab reduces acute liver allograft rejection in pediatric patients. Transplant Proceedings 2002: 34: 2374-2375.
6. AW MM, TAYLOR RM, VERMA A, et al. Basiliximab (simulect) for the treatment of steroid-resistant rejection in pediatric liver transplant recipients: a preliminary experience. Transplantation 2003: 75: 796-799.
7. KNECHTLE SJ, VARGO D, FECHNER J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997: 63: 1-6.
8. KRIEGER NR, KNECHTLE SJ. Novel immunosuppressive agents in tolerance induction. Current Drug Targets-Cardiovasc and Haemat Dis 2002: 2: 97-103.
9. CONTRERAS JL, WANG PX, ECKHOFF DE, et al. Peritransplant tolerance induction with anti-CD3-immunotoxin: a matter of proinflammatory cytokine control. Transplantation 1998: 65: 1159-1169.
10. THOMAS JM, CONTRERAS JL, JIANG XL, et al. Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation 1999: 68: 1660-1673.
11. NEVILLE DM Jr, SCHARFF J, SRINIVASACHAR K. In vivo T-cell ablaion by a holo-immunotoxin directed at human CD3. Proc Natl Acad Sci USA 1992: 89: 2585-2589.
12. THOMAS FT, RICORDI C, CONTRERAS JL, et al. Reversal of naturally occuring diabetes in primates by unmodified islet xenografts without chronic immunosuppression. Transplantation 1999: 67: 846-854.
13. WEETALL M, DIGAN ME, HUGO R, et al. T-cell depletion and graft survival induced by anti-human CD3-immunotoxins in human CD3epsilon transgenic mice. Transplantation 2002: 73: 1658-1666.
14. CALNE R, MOFFATT SD, FRIEND PJ, et al. Campath 1H allows low-dose monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999: 68: 1613-1616.
15. KNECHTLE SJ, PIRSCH JD, FECHNER J, et al. Campath-1H induction plus rapmycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003: 3: 722-730.
16. KIRK AD, HALE DA, MANNON RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monclonal antibody alemtuzumab (CAM-PATH-1H). Transplantation 2003: 76: 120-129.
17. HAMAWY MM, CHO CS, KNECHTLE SJ. Therapeutic Immunosuppression. Dordrecht: Kluwer Academic Pulbishers, 2001.
18. SAYEGH MH, TURKA LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998: 338: 1813-1821.
19. KIRK AD, HARLAN DM, ARMSTRONG NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection iin primates. Proc Natl Acad Sci USA 1997: 94: 8789-8794.
20. LEVISETTI MG, PADRID PA, SZOT GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997: 159: 5187-5191.
21. KIRK AD, BURKLY LC, BATTY DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999: 5: 686-693.
22. CHANG AC, BLUM MG, BLAIR KS, et al. Prolonged anti-CD40 ligand therapy improves primate cardiac allograft survival. Transplant Proc 1999: 31: 95.
23. PEARSON TC, TRAMBLEY J, ODOM K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002: 74: 933-940.
24. LARSEN CP, ELWOOD ET, ALEXANDER DZ, et al. Long-tern acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996: 381: 434-438.
25. MORRIS RE. Rapamycins: antifungal antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992: 6: 39.
26. SEHGAL SN. Rapamune (sirolimus, rapamycing): an overview and mechanism of action. Ther Drug Monit 1995: 17: 660.
27. KAHAN BD, JULIAN BA, PESCOVITZ MD, VANRENTERGHEM Y, NEYLAN J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation 1999: 68: 1526-1532.
28. CIANCIO G, BURKE GW, GAVNOR JJ, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (neoral) and sirolimus in renal transplantiation. I. Drug interactions and rejection at one year. Transplantation 2004 77: 244-251.
29. BUDDE K, SCHMOUDER RL, BRUNKHORST R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002: 13: 1073.
30. KAHAN BD. FTY720: a new dimension in transplantation. Transplant Proc 2001: 33: 3081.
31. NIKOLOVA Z, HOF A, BAUMLIN Y, HOF RP. Combined FTY720/cyclosporine treatment promotes graft survival and lowers the peripheral lymphocyte count in a murine cardiac allotransplantation model. Transplantation 2001: 72: 168.
32. WANG ME, TEJPAL N, QU X, et al. Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus. Transplantation 1998: 65: 899.
33. SUZUKI S, ENOSAWA S, KAKEFUDA T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996: 61: 200.
34. TAKEUCHI T, IINUMA H, KUNIMOTO S, et al. A new antitumor antibiotic, spergualin: isolation and antitumor activity. Antibiotics 1981: 34: 1619-1621.
35. HIBASHAMI H, TSUKADA T, SUZUKI R, et al. Deoxyspergualin, an antiproliferative agent, shows inhibitory effects on synthetic pathway of polyamines. Anticancer Res 1991: 11: 325-330.
36. UMEDA Y, MORIGUCHI M, KUROND H, et al. Synthesis and antitumor activity of spergualin analogues: I. Chemical modification of 7-guanidine-3-hydroxyacyl moiety. J Antibiot 1985: 38: 886-898.
37. WALTER P, FEIFEL G, SHORLEMMER H, et al. A new immunoosuppressive active antitumoral drug 15-deoxyspergualin prevents rejection of allogeneic transplanted islets. Transplant Proc 1986: 18: 1860-1861.
38. OCHIAI T, HORI S, NAKAJIMA K, et al. Prolongation of rat heart survival by 15-deoxyspergualin. J Antibiot 1987: 40: 249-250.
39. THIES JC, WALTER PK, ZIMMERMANN FA, et al. Prolongation of graft survival in allogeneic pancreas anad liver transplantation by 15-deoxyspergualin. Eur Surg Res 1987: 19: 129-134.
40. UMEZAWA H, ISHIZUKA M, TAKEUCHI K, et al. Suppression of tissue graft rejection by spergualin. J Antibiot 1985: 38: 283-284.
41. MASUDA T, MIZUTANI S, IIJIMA M, et al. Immunosuppressive effects of 15-deoxyspergualin and its effect on skin allografts in rats. J Antibiot 1987: 40: 1612-1618.
42. WAAGA AM, KRZYMANSKI M, ULRICHS K, OKO A, MULLER-RUCHHOLTZ W. Induction of specific tolerance by 15-deoxyspergualin (DOS) treatment after rat skin and kidney transplantation in rats. Analysis of effectively of various protocols of DOS application. Arch Immunol Ther Exp (Warsz) 1996: 44: 143.
43. KEER PG, ATKINS RC. The effects of deoxyspergualin on lymphocytes and monocytes in vivo and in vitro. Transplantation 1989: 48: 1048.
44. AMEMIYA H, SUZUKI S, OTA K, et al. A novel rescue drug, 15-deoxyspergualin. Transplantation 1990: 49: 337.
45. AMEMIYA H. Deoxyspergualin: clinical trials in renal graft rejection. Ann NY Acad Sci 1993: 685: 196.
46. KYO M, ICHIKAWA Y, FUKUNISHI Y, et al. Histopathologic classification and clinical effects of kidney transplant rejection treated with 15-deoxyspergualin. Transplant Proc 1995: 27: 1012.
47. Amemiya and Japanese Collaborative Transplant Study Group of NKT-01. Immunosuppressive mechanism and action of deoxyspergualin in experimental and clinical studies. Transplant Proc 1995: 27: 31.
48. MARGAY S, DUTARTRE P, GLUCKMAN E. Effect of tresperimus on in tiro human Tresperimus, an analogue of 15-deoxyspergualin (15-DSG), immunosuppressive and prevents lethal graft-versus-host disease following allogeneic bone marrow transplantation cell differentiation. Kidney Int 2001: 60: 1354.
49. KASAI M, HIGA T, NAOHARA T, et al. 15-Deoxyspergualin controls cyclosporin- and steroid-resistant intestinal acute graft-versus-host disease following allogeneic bone marrow transplantation. Bone Marrow Transplant 1994: 14: 315.
50. YANG H, KANAI N, GARCIA B, et al. LF-0195, an analogue of 15-deoxyspergualin (DSG) monotherapy significantly prolonged renal allograft survival in monkeys. Amer J of Transpl 2002: 2: 361.
51. SILVA HT, MORRIS RE. Leflunomide and malononitrilamides. Amer J Med Sci 1997: 313: 289.
52. CHONG AS, HUANG W, LIU W, et al. In vivo activity of leflunomide: pharmacokinetics analyses and mechanism of immunosuppression. Transplantation 1999: 68: 100.
53. CAO WW, KAO PN, CHAO AC, GARDNER P, NG J, MORRIS RE. Mechanism of the antiproliferative action of leflunomide: A771726, the active metabolite of leflunomide, does not block T cell receptor-mediated signal transduction but its antiproliferative effects antagonized by pyrimidine nucleosides. J Heart Lung Transplant 1995: 14: 1016.
54. DAVIS JP, CAIN GA, PITTS WJ, MAGOLDA RL, COPELAND RA. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroontate dehydrogenase. Biochemistry 1996: 35: 1270.
55. GREENE S, WATANABE K, BRAATZ-TRULSON J, LOU L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995: 50: 861.
56. ELDER RT, XU X, WILLIAMS JA, GONG H, FINNEGAN A, CHONG AS. The immunosuppressive metabolite of leflunomide, A771726, affects murine T cells through two biochemical. J Immunol 1997: 159: 22.
57. WILLIAMS JA, MITAL D, CHONG A, et al. Experience with leflunomide in solid organ transplanation. Transplantation 2002: 73: 358.
58. MLADENOVIC V, DOMLJAN Z, ROZMAN B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rhematoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995: 38: 1595.
59. KURRLE R, BARLETT RR, RUUTH E, LAUFFER L, SCHORLEMMER HU. Malononitrilamides inhibit T- and B-cell responsiveness. Transplant Proc 1996: 28: 3053.
60. KURRLE R, BARLETT RR, RUUTH E, LAUFFER L, SCHORLEMMER HU. Malononitrilamides inhibit T- and B-cell responsiveness in different species. Transplant Proc 1997: 29: 1302.
61. SCHORLEMMER HU, BARLETT RR, KURRLE R, RUUTH E. Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus. Transplant Proc 1998: 30: 4099.
62. MORRIS RE, HUANG X, CAO W, ZHENG B, SHORTHOUSE RA. Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection, and anti-donor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury. Transplant Proc 1995: 27: 445.
63. CHEN H, QI S, XU D, et al. Significant prolongation of renal allograft survival by delayed combination of FK778 with tacrolimus in non-human primates. Am J Transplant 2002: 2: 361.
64. LUKE PP, O'Brien CA, JEVNIKAR AM, ZHONG R. Anti-CD45RB monoclonal antibody-mediated transplantation tolerance. Curr Mol Med 2001: 1: 533-543.